Ankaferd hemostatic
Topical Gauze

Description

Ankaferd hemostatic topical gauze – Ankaferd BloodStopper (ABS) links to life…
Ankaferd Bloodstopper is a stable and sterile medical product of standard vegetable content which serves as a haemostasis regulator and displays fast haemostatic effect when
applied to control minor or major hemorrhages due to exterior wounds, traumatic cuts,
dental operations, spontaneous or surgical procedures.

Formula

100 ml product contains; Urtica dioica (dried root extract) 6 mg, Vitis vinifera (dried leaf
extract) 8 mg, Glycrrhiza glabra (dried leaf extract) 9 mg, Alpinia officinarum (dried leaf
extract) 7 mg, Thymus vulgaris (dried grass extract) 5 mg.

EffecƟve Mechanism

Independent of the classic coagulation cascade system, Ankaferd Bloodstopper shows
haemostatic effect in a protein network environment through vital physiological erythrocyte aggregation. This process takes place in a matter of split seconds in vitro and seconds in vivo environments.

Medical Property
Ankaferd Bloodstopper, a hemorrhage stopping preparation, forms a network inside plazma or serum fast (in a
matter of split seconds). General haemostatic and biochemical tests have shown that the mentioned network is
formed via the interaction between Ankaferd Bloodstopper
and proteins in blood; but primarily via the products interaction with fibrinogen. The tests also show that red spheres
provide vital aggregation. At this stage, the process of holding hemorrhage at a certain level to allow tissue repair/
restoration is primarily related with protein erythrocyte interaction. Blood cells too take their part in the network. Independent of the physiological haemostatic process tissue
factor related to blood coagulation, Ankaferd Bloodstopper,
developes without effecting this system. Therefore Ankaferd Bloodstopper is not only
effective on patients with normal haemostatic values, but also on those who are primary and secondary haemostasis defective. Ankaferd Bloodstopper can be employed as an
aide product in clinique procedures for stopping intensive dental hemorrhaging, including mucousal fissures. Ankaferd BloodStopper must not be injected into vein or blood
circulation system.

Ankaferd Blood Stopper can be used in
many areas
Ambulances, emergency wards, first aid centers, hospitals, dental clinics, health units, police forces, armed
forces, fire departments, natural disaster zones, search
and rescue teams, first aid kits, schools, homes, offices,
land/air/sea transport vehicles…

Ankaferd BloodStopper provides fast
haemostasis, independent of blood coagulation factors
Ankaferd BloodStopper is effective and safe in controlling external and teeth hemorrhage of patients hemophilic, diabetic and those using anti coagulan (Coumadin) and
anti-aggregator (Aspirin, Heparin).
Ankaferd BloodStopper is 100% vegetal and contains no inorganic/synthetic additives
and alcohol does not cause irritation is sterile and will not lose this property does away
with germs inside and around applied area has no allergic effect does not pose a risk to
human health is in liquid form, therefore very easy to apply does not need to be
cleaned off the area applied has no special storage condition, does not need cold chain

Side/ Adverse Effects
Ankaferd BloodStopper has no known side effect. If an undesired effect is seen contact
Usercare Medical.

Drug Interaction and Other Interactions
Ankaferd BloodStopper has no known adverse interaction with drugs used by patients.
Hypoallergenic.

Commercial Presentation Form
Ankaferd BloodStopper is currently on sale in the following packages:
Ankaferd BloodStopper Tampon: (2.5cm x 7cm 3ml.)-(5cm x 7,5cm- 10ml.)-(20cm x
20cm -100ml)
Ankaferd Tampons in a box.
Ankaferd BloodStopper Spray: 5ml, 10ml, 25ml, 50ml and 100ml.
Ankaferd BloodStopper Ampule: (24 units)

Usage areas of Ankaferd Bloodstopper
GENERAL SURGERY
· All gastrointestinal (esophagus, stomach, liver, gallbladder, pancreas, small bowel,
colon, appendix) operations.
· All endoscopic and colonoscopy procedures.
· Thyroid surgeries.
· Breast surgery.
· Circumcision.
· Hernia operations.
· Hemorrhoidectomy

GASTROENTEROLOGY
· Upper and lower gastrointestinal system (GIS) bleeding control
· All endoscopic and colonoscopy procedures

GYNAECOLOGY & OBSTETRICS
· Atony bleeding
· Caesarean section
· Hysterectomy
· Endometriosis and other gynecological mass surgeries
· Oncological surgeries and pelvic floor surgery

EMERGENCY USE
· Thoracic injuries Extremity injuries
· Bleeding control in trauma patients using
· Heparin, Aspirin, Warfarin
· Bleeding control in patients with bleeding-coagulation disorders
· Challenging and uncontrollable bleeding

THORASIC SURGERY
· Thoracic injuries
· Pulmonary lobectomy-wedge resections
· Mediastinal mass-tumor surgeries and all other mediastinal operations

UROLOGY
· Scrotal orchiopexy, varicocele and all scrotal surgeries (mass, tumor, etc.)
· Open and closed prostate surgeries Bladder operations

PULMONOLOGY
· Bronchoscopy

THORASIC SURGERY
· Von Willebrand
· Afibrinogenemia
· Hemophilia
· Diabetes
· Lack of factor
· Hereditary thrombocytopenia
· In acquired bleeding diathesis due to various systematic diseases (Nephrotic, hepatic
insufficiency, etc.)
· In acquired bleeding diathesis due to drug use (Warfarin, Heparin, Aspirin etc.)
· Glanzmann’s thrombasthenia

CARDIOVASCULAR SURGERY
· All open and closed heart operations Coronary bypass surgery Heart valve surgeries
· Major vessel surgeries (aneurysm, dissection) Varicose and peripheral artery surgeries

ENT (OTOLARYNGOLOGY)
· All head and neck surgery operations (neck dissection, tumor-mass removal)
· All intraoral surgeries and tonsillectomy
· Rhinoplasty
· Epistaxis

ORTHOPEDICS AND TRAUMATOLOGY
· All orthopedic trauma, arthroplasty and revision surgeries
· Spinal surgery
· Hand-foot surgery and orthopedic oncology surgeries

DENTAL USAGE AREAS
· Complicated or normal tooth extraction operations
· Bleeding during and after implantation procedures
· Cyst operations
· Control of bleeding during detertrage, curettage, gingivectomy, gingivoplasty procedures
· All other intraoral dental operations In order to accelerate healing in patients with
systematic diseases in which wound healing is thought to be delayed,
· Intraoral operations in patients using Heparin, Asprin, Warfarin
· Diabetes, Hemophilia, Von Willebrand etc.
· Intraoral operations of bleeding diathesis patients

NEPHROLOGY
· Arterial and vein bleeding due to dialysis

Effective for Patients
The network formed by Ankaferd Blood Stopper® (ABS) affects the entire physiological
hemostasis process without specifically affecting any coagulating factor. Therefore, ABS
is effective both in individuals with normal hemostasis parameters and in patients with
primary and/or secondary hemostasis insufficieny, including disseminated intravascular
coagulation.
ABS provides an effective hemostasis in the following conditions/diseases that prolong
bleeding time.
· Von Willebrand
· Afibrinogenemia
· Hemophilia
· Diabetes
· Lack of factor
· Hereditary thrombocytopenia
· In acquired bleeding diathesis due to various systematic diseases (Nephrotic, hepatic
insufficiency, etc.)
· In acquired bleeding diathesis due to drug use (Warfarin, Heparin, Aspirin etc.)
· Glanzmann’s trhombasthenia

Fast & Strong
Ankaferd Blood Stopper® (ABS) stimulates the formation of an encapsulated protein
network containing fibrinogen, total protein, albumin and globin very quickly (< 1 second), and erythrocytes and platelets aggregate on this network. Ankaferd Blood Stopper acts on the primary and secondary hemostatic system without disturbing the coagulation factors, thanks to the protein network it stimulates the formation of blood cells
and especially erythrocytes.
ABS is an easy-to-use, ideal topical hemostatic agent that is effecƟve not only in venous
bleeding but also in high-pressure arterial bleeding.
Figure 1. The basic mechanism of action of
Ankaferd Blood Stopper (ABS) is the formation of
an encapsulated protein network that provides
focal points for erythrocyte aggregation. ABSrelated formation of the unique protein network
in vital erythroid aggregation covers the entire
physiological hemostatic process. Red blood cell
(RBC) elements (such as spectrin and ankrin surface receptors and the internal ferrochelatase enzyme), related transcription factors (such as GATA
-1), and RBC-related proteins (such as urotensin II)
are the main targets of abs. These proteins and
the necessary ATP bioenergy are included in the
Ankaferd protein library.